-
公开(公告)号:EP1529530B3
公开(公告)日:2009-09-02
申请号:EP04028298.0
申请日:2002-08-15
申请人: AstraZeneca AB
发明人: Johnstone, Craig , James, Roger , Mckerrecher, Darren , Boyd, Scott , Caulkett, Peter , Hargreaves, Rodney , Jones, Clifford David , Bowker, Suzanne , Block, Michael Howard
IPC分类号: A61K31/425 , C07D417/12 , C07D233/48 , C07D285/12 , C07D213/75 , C07D241/20 , C07D231/40 , C07D237/20 , C07D239/42 , C07D307/66
CPC分类号: C07D213/75 , A61K31/165 , A61K31/195 , A61K31/425 , A61K31/445 , C07D213/82 , C07D213/85 , C07D231/40 , C07D233/48 , C07D237/20 , C07D237/24 , C07D239/42 , C07D241/20 , C07D241/26 , C07D261/14 , C07D277/46 , C07D277/56 , C07D277/82 , C07D285/135 , C07D307/66 , C07D401/04 , C07D403/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14
-
公开(公告)号:EP2076489A1
公开(公告)日:2009-07-08
申请号:EP07730131.5
申请日:2007-06-13
IPC分类号: C07C311/21 , C07C311/37 , C07D233/48 , C07D239/14 , A61K31/18 , A61P25/00
CPC分类号: C07C311/21 , C07C311/37 , C07C2602/10 , C07D233/48 , C07D233/88 , C07D239/14
摘要: Compounds of the formula I or pharmaceutically acceptable salts thereof, wherein Ar, X, m, R1, R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I for treatment of 5-HT6-mediated diseases.
摘要翻译: 式I化合物或其药学上可接受的盐,其中Ar,X,m,R1,R2如本文所定义。 还提供了用于制备包含式I化合物的组合物,组合物和方法用于治疗5-HT 6介导的疾病的方法。
-
公开(公告)号:EP1695705B1
公开(公告)日:2008-08-06
申请号:EP06009486.9
申请日:2002-08-15
申请人: AstraZeneca AB
发明人: Johnstone, Craig , James, Roger , McKerrecher, Darren , Boyd, Scott , Caulkett, Peter , Hargreaves, Rodney , Jones, Clifford David , Bowker, Suzanne , Block, Michael Howard
IPC分类号: A61K31/425 , C07D417/12 , C07D233/48 , C07D285/12 , C07D213/75 , C07D241/20 , C07D231/40 , C07D237/20 , C07D239/42 , C07D307/66 , A61P3/10
CPC分类号: C07D213/75 , A61K31/165 , A61K31/195 , A61K31/425 , A61K31/445 , C07D213/82 , C07D213/85 , C07D231/40 , C07D233/48 , C07D237/20 , C07D237/24 , C07D239/42 , C07D241/20 , C07D241/26 , C07D261/14 , C07D277/46 , C07D277/56 , C07D277/82 , C07D285/135 , C07D307/66 , C07D401/04 , C07D403/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14
-
公开(公告)号:EP1661563B1
公开(公告)日:2008-05-28
申请号:EP06001808.2
申请日:2002-08-15
申请人: AstraZeneca AB
发明人: Johnstone, Craig, AstraZeneca , James, Roger, AstraZeneca , Mckerrecher, Darren, AstraZeneca , Boyd, Scott, AstraZeneca , Caulkett, Peter, AstraZeneca , Hargreaves, Roney , AstraZeneca , Jones, Cliford David, AstraZeneca , Bowker, Suzanne, AstraZeneca , Block, Michael Howard, AstraZeneca
IPC分类号: A61K31/25
CPC分类号: C07D213/75 , A61K31/165 , A61K31/195 , A61K31/425 , A61K31/445 , C07D213/82 , C07D213/85 , C07D231/40 , C07D233/48 , C07D237/20 , C07D237/24 , C07D239/42 , C07D241/20 , C07D241/26 , C07D261/14 , C07D277/46 , C07D277/56 , C07D277/82 , C07D285/135 , C07D307/66 , C07D401/04 , C07D403/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14
-
公开(公告)号:EP1768951A2
公开(公告)日:2007-04-04
申请号:EP05790012.8
申请日:2005-06-17
发明人: DIX, Thomas, A.
IPC分类号: C07C229/00 , C07C205/00 , C07C57/30 , C07D231/06
CPC分类号: C07C279/14 , A61K38/00 , C07C229/08 , C07C229/12 , C07C257/14 , C07D231/06 , C07D233/46 , C07D233/48 , C07D239/14 , C07K7/083
摘要: This invention relates to non-natural desamino alkyl amino acid compounds, methods of making, and peptides containing these compounds as their N-terminus moieties. A preferred example is neurotensin (8-13) in which the N terminus is an alpha desamino, alpha methyl N,N dimethyl homolysine residue.
-
公开(公告)号:EP1711458A1
公开(公告)日:2006-10-18
申请号:EP05700969.8
申请日:2005-01-17
申请人: Merck Patent GmbH
IPC分类号: C07C277/08 , C07C279/04 , C07D233/48 , C07D233/28 , C07C211/15
CPC分类号: C07D233/28 , C07C211/15 , C07C277/08 , C07D233/48 , C07F9/28 , C07C279/04
摘要: The invention relates to a two-stage method for producing guanidinium salts of formula (1), wherein the substituents R have the designation cited in patent claim 1, and A- is a sulfonate, an alkyl or aryl sulfate, a hydrogen sulfate, a imide, a methanide, a carboxylate, a phosphate, a phosphinate, a phosphonate, a borate, a thiocyanate, a perchlorate, a fluorosilicate or a nitrate. The invention also relates to intermediate compounds produced by said method.
-
公开(公告)号:EP1661569A1
公开(公告)日:2006-05-31
申请号:EP06001807.4
申请日:2002-08-15
申请人: AstraZeneca AB
发明人: Johnstone, Craig, AstraZeneca , James, Roger, AstraZeneca , Mckerrecher, Darren, AstraZeneca , Boyd, Scott, AstraZeneca , Caulkett, Peter, AstraZeneca , Hargreaves, Roney , AstraZeneca , Jones, Cliford David, AstraZeneca , Bowker, Suzanne, AstraZeneca , Block, Michael Howard, AstraZeneca
IPC分类号: A61K31/425
CPC分类号: C07D213/75 , A61K31/165 , A61K31/195 , A61K31/425 , A61K31/445 , C07D213/82 , C07D213/85 , C07D231/40 , C07D233/48 , C07D237/20 , C07D237/24 , C07D239/42 , C07D241/20 , C07D241/26 , C07D261/14 , C07D277/46 , C07D277/56 , C07D277/82 , C07D285/135 , C07D307/66 , C07D401/04 , C07D403/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14
摘要: The invention relates to compounds of Formula (IIg) or a salt, solvate or prodrug thereof, wherein R 3 , X and Z 1 are as described in the specification, methods of preparing them and their use for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes.
摘要翻译: 本发明涉及式(IIg)化合物或其盐,溶剂合物或前药,其中R 3,X和Z 1如说明书中所述,其制备方法及其用于治疗或预防疾病状况 通过葡萄糖激酶(GLK)介导,如2型糖尿病。
-
8.
公开(公告)号:EP1644337A1
公开(公告)日:2006-04-12
申请号:EP04776621.7
申请日:2004-06-15
申请人: Gene Logic, Inc.
发明人: VOS, Tricia, J. , SOLOMON, Michael, E. , CLAIBORNE, Christopher, F. , MAGUIRE, Martin , DAI, Mingshi , PATANE, Michael , MARSILJE, Thomas, H.
IPC分类号: C07D233/06 , C07D233/20 , C07D233/22 , C07D235/18 , C07D233/42 , C07D233/48 , C07D409/04 , C07D401/04 , C07D513/04 , C07D471/04 , C07D487/04 , C07D405/10 , C07D409/10 , C07D403/10 , C07D405/14
CPC分类号: C07D471/04 , A61K31/4164 , A61K31/4174 , A61K31/4184 , A61K31/505 , A61K31/5377 , C07C211/27 , C07C211/29 , C07C211/30 , C07C237/38 , C07C257/18 , C07C271/20 , C07C275/26 , C07D233/06 , C07D233/10 , C07D233/18 , C07D233/20 , C07D233/22 , C07D233/26 , C07D233/30 , C07D233/42 , C07D233/48 , C07D235/12 , C07D235/18 , C07D239/06 , C07D295/073 , C07D295/088 , C07D295/13 , C07D295/135 , C07D401/04 , C07D403/14 , C07D405/10 , C07D405/14 , C07D409/04 , C07D409/10 , C07D409/12 , C07D487/04 , C07D513/04
摘要: Provided are MC4-R binding compounds of the formula XVII: (XVII), wherein L2 is a linker group, and P1, P2, P3, P4, Z1, Z2, Z3, Z4, Z5, t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.
-
公开(公告)号:EP1636173A2
公开(公告)日:2006-03-22
申请号:EP04724995.8
申请日:2004-04-01
申请人: Merck Patent GmbH
IPC分类号: C07C279/02 , C07D279/04 , C07D233/48 , C07F9/28 , C07C309/06 , C07F5/02 , C07C277/08
CPC分类号: C07D233/48 , C07C277/08 , C07C279/02 , C07C279/04 , C07D233/02 , C07F5/04 , C07F9/28
摘要: The invention relates to salts containing guanidinium cations, to a method for their production and to their use as ionic liquids.
-
公开(公告)号:EP1420784A1
公开(公告)日:2004-05-26
申请号:EP02755165.4
申请日:2002-08-15
申请人: Astrazeneca AB
发明人: BOYD, Scott , CAULKETT, Peter, William, Rodney , HARGREAVES, Rodney, Brian , BOWKER, Suzanne, Saxon , JAMES, Roger , JOHNSTONE, Craig , JONES, Clifford, David , MCKERRECHER, Darren , BLOCK, Michael, Howard
IPC分类号: A61K31/425
CPC分类号: C07D213/75 , A61K31/165 , A61K31/195 , A61K31/425 , A61K31/445 , C07D213/82 , C07D213/85 , C07D231/40 , C07D233/48 , C07D237/20 , C07D237/24 , C07D239/42 , C07D241/20 , C07D241/26 , C07D261/14 , C07D277/46 , C07D277/56 , C07D277/82 , C07D285/135 , C07D307/66 , C07D401/04 , C07D403/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14
摘要: The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R?1, R2, R3¿, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).
-
-
-
-
-
-
-
-
-